{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:25:18Z","timestamp":1790418318335,"version":"4.1.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A serious complication of aplastic anemia (AA) is its evolution to clonal hematologic diseases such as myelodysplasia (MDS) and leukemia, which is usually associated with the appearance of a cytogenetic abnormality in bone marrow cells. We present here an analysis of a cohort of 30 patients with otherwise typical AA in whom clonal karyotypic evolution was observed during frequent periodic marrow examinations. The actuarial risk for this complication has been estimated in other studies at around 15% at 5 years. Conversion from normal to abnormal karyotype occurred at a constant rate after initial diagnosis, with about 50% of cases developing within the first 30 months. Transient chromosomal abnormalities were infrequent. Clinically, AA patients with clonal cytogenetic patterns were heterogenous; a variety of karyotypic defects with numerical and structural abnormalities of chromosome 7 accounted for 40% of all cases followed by trisomy 8, structural and numerical abnormalities of chromosome 13, deletion of Y chromosome, and complex cytogenetic abnormalities. Unlike in primary MDS, aberrancies of chromosome 5 and 20 were infrequent. The clinical course depended on the specific abnormal cytogenetic pattern. Most deaths related to leukemic transformation occurred in patients with abnormalities of chromosome 7 or complex cytogenetic alterations or both. Evolution of chromosome 7 abnormalities was seen most often in refractory patients who had failed to respond to therapy. In contrast, trisomy 8 developed in patients with good hematologic responses who often required chronic immunosuppression with cyclosporine A (CsA), and survival was excellent. Although AA patients with monosomy 7 showed a similar prognosis to those with primary MDS, trisomy 8 in AA appears to have a more favorable prognosis than in MDS.<\/jats:p>","DOI":"10.1182\/blood.v99.9.3129","type":"journal-article","created":{"date-parts":[[2002,10,11]],"date-time":"2002-10-11T18:33:52Z","timestamp":1034361232000},"page":"3129-3135","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":210,"title":["Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia"],"prefix":"10.1182","volume":"99","author":[{"given":"Jaroslaw P.","family":"Maciejewski","sequence":"first","affiliation":[{"name":"From the Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Risitano","sequence":"additional","affiliation":[{"name":"From the Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine M.","family":"Sloand","sequence":"additional","affiliation":[{"name":"From the Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Nunez","sequence":"additional","affiliation":[{"name":"From the Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal S.","family":"Young","sequence":"additional","affiliation":[{"name":"From the Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021221165019300_B1","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1182\/blood.V85.12.3367.bloodjournal85123367","article-title":"The treatment of severe acquired aplastic anemia.","volume":"95","author":"Young","year":"1995","journal-title":"Blood."},{"key":"2020021221165019300_B2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.7326\/0003-4819-131-6-199909210-00002","article-title":"Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes.","volume":"131","author":"Dunn","year":"1999","journal-title":"Ann Intern Med."},{"key":"2020021221165019300_B3","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1046\/j.1365-2141.2001.03191.x","article-title":"Clinical features of the relationship between aplastic anemia and paroxysmal nocturnal hemoglobinuria.","volume":"115","author":"Maciejewski","year":"2001","journal-title":"Br J. Hematol."},{"key":"2020021221165019300_B4","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2141.1988.tb02382.x","article-title":"Late hematologic complications in severe aplastic anemia.","volume":"69","author":"Tichelli","year":"1988","journal-title":"Br J Haematol."},{"key":"2020021221165019300_B5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.7326\/0003-4819-126-2-199701150-00003","article-title":"Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy.","volume":"126","author":"Doney","year":"1997","journal-title":"Ann Intern Med."},{"key":"2020021221165019300_B6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0037-1963(00)90033-7","article-title":"Tichelli A. Late clonal complications of aplastic anemia.","volume":"37","author":"Socie","year":"2000","journal-title":"Semin Hematol."},{"key":"2020021221165019300_B7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1046\/j.1365-2141.1999.01187.x","article-title":"Abnormal cytogenetic clone in patients with aplastic anemia: response to immunosuppressive therapy.","volume":"104","author":"Geary","year":"1999","journal-title":"Br J Hematol."},{"key":"2020021221165019300_B8","first-page":"418","article-title":"Cytogenetic abnormalities in patients with severe aplastic anemia.","volume":"81","author":"Mikhailova","year":"1996","journal-title":"Haematologica."},{"key":"2020021221165019300_B9","first-page":"1134","article-title":"Clonal cytogenetic abnormalities in patients with otherwise typical aplastic anemia.","volume":"5","author":"Appelbaum","year":"1987","journal-title":"Exp Hematol."},{"key":"2020021221165019300_B10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2141.1989.tb00230.x","article-title":"Long-term follow up of severe aplastic anemia patients treated with antithymocyte globulin.","volume":"73","author":"De Planque","year":"1989","journal-title":"Br J Hematol."},{"key":"2020021221165019300_B11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1006\/bcmd.1997.0138","article-title":"The evidence for clonal evolution with monosomy 7 in aplastic anemia following granulocyte colony-stimulating factor using the polymerase chain reaction.","volume":"23","author":"Yamazaki","year":"1997","journal-title":"Blood Cells Mol Dis."},{"key":"2020021221165019300_B12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1182\/blood.V85.1.283.bloodjournal851283","article-title":"Long-term outcome of aplastic anemia in adults treated with anti-thymocyte globulin: comparison with bone marrow transplantation.","volume":"85","author":"Plaquette","year":"1996","journal-title":"Blood."},{"key":"2020021221165019300_B13","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1056\/NEJM199310143291603","article-title":"Malignant tumors occurring after treatment of aplastic anemia.","volume":"329","author":"Socie","year":"1993","journal-title":"N Engl J Med."},{"key":"2020021221165019300_B14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2141.1988.tb02434.x","article-title":"Evolution of acquired severe aplastic anemia to myelodysplasia and subsequent leukemia in adults.","volume":"70","author":"De Planque","year":"1988","journal-title":"Br J Haematol."},{"key":"2020021221165019300_B15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s002770050341","article-title":"Aplastic anemia or aplastic preluekemic syndrome?","volume":"75","author":"Jameel","year":"1997","journal-title":"Ann Hematol."},{"key":"2020021221165019300_B16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood.V48.1.63.63","article-title":"Severe aplastic anemia: a prospective study of the effect of early bone marrow transplantation on acute mortality.","volume":"48","author":"Camitta","year":"1976","journal-title":"Blood."},{"key":"2020021221165019300_B17","first-page":"181","article-title":"Proposal for the classification of the myelodysplastic syndromes.","volume":"51","author":"Bennett","year":"1986","journal-title":"Br J Hematol."},{"key":"2020021221165019300_B18","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes.","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood."},{"key":"2020021221165019300_B19","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood.V85.11.3058.bloodjournal85113058","article-title":"Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia.","volume":"85","author":"Rosenfeld","year":"1995","journal-title":"Blood."},{"key":"2020021221165019300_B20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/1096-8652(200103)66:3<167::AID-AJH1040>3.0.CO;2-R","article-title":"Bone marrow cytogenetic abnormalities of aplastic anemia.","volume":"66","author":"Yi-Kong","year":"2001","journal-title":"Am J Hematol."},{"key":"2020021221165019300_B21","first-page":"133","article-title":"Cytogenetic abnormalities in 532 patients with myeloid leukemias and myelodysplastic syndrome. The Czechoslovak MDS Cooperative Group.","volume":"13","author":"Michalova","year":"1999","journal-title":"Czech Med."},{"key":"2020021221165019300_B22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF01728788","article-title":"Correlations between cytogenetics and morphology in myelodysplastic syndromes.","volume":"60","author":"Vila","year":"1990","journal-title":"Blut"},{"key":"2020021221165019300_B23","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/ajh.2830460404","article-title":"Karyotype in myelodysplastic syndrome: relations to morphology, clinical evolution and survival.","volume":"46","author":"Bernasconi","year":"1994","journal-title":"Am J Hematol."},{"key":"2020021221165019300_B24","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0025-6196(12)60566-7","article-title":"Cytogenetic studies in 174 consecutive patients with preleukemic or myelodysplastic syndromes.","volume":"60","author":"Knapp","year":"1985","journal-title":"Mayo Clin Proc."},{"key":"2020021221165019300_B25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0165-4608(90)90193-E","article-title":"Results of chromosome studies and their relation to morphology, course and prognosis in 120 patients with de novo myelodysplastic syndrome.","volume":"44","author":"Succiu","year":"1990","journal-title":"Cancer Genet Cytogenet."},{"key":"2020021221165019300_B26","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/(SICI)1096-8652(199712)56:4<224::AID-AJH5>3.0.CO;2-Z","article-title":"MDS and AML with trisomy 8 as a sole chromosome aberration show different sex ratios and prognostic profiles: a study of 115 published cases.","volume":"56","author":"Pedersen","year":"1997","journal-title":"Am J Hematol."},{"key":"2020021221165019300_B27","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1046\/j.1365-2141.2000.01868.x","article-title":"Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes.","volume":"108","author":"Sole","year":"2000","journal-title":"Br J Hematol."},{"key":"2020021221165019300_B28","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0145-2126(00)00056-4","article-title":"Chromosomal alterations associated with evolution from myelodysplastic syndrome to acute myeloid leukemia.","volume":"24","author":"Sousa de Feranadez","year":"2000","journal-title":"Leuk Res."},{"key":"2020021221165019300_B29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/(SICI)1098-2264(200001)27:1<11::AID-GCC2>3.0.CO;2-I","article-title":"Clinical significance of Y chromosome loss in hematologic disease.","volume":"27","author":"Wiktor","year":"2000","journal-title":"Genes Chromosomes Cancer."},{"key":"2020021221165019300_B30","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial.","volume":"92","author":"Grimwalde","year":"1998","journal-title":"Blood."},{"key":"2020021221165019300_B31","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","article-title":"Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group study.","volume":"96","author":"Slovak","year":"2000","journal-title":"Blood."},{"key":"2020021221165019300_B32","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0889-8588(05)70119-2","article-title":"Cytogenetic abnormalities in multiple myeloma.","volume":"13","author":"Fonseca","year":"1999","journal-title":"Hematol Oncol Clin North Am."},{"key":"2020021221165019300_B33","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ajh.2830490319","article-title":"Unusual clonal cytogenetic abnormalities in aplastic anemia [letter].","volume":"49","author":"Varma","year":"1995","journal-title":"Am J Hematol."},{"key":"2020021221165019300_B34","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood.V90.3.1009","article-title":"Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia.","volume":"90","author":"Ohara","year":"1997","journal-title":"Blood."},{"key":"2020021221165019300_B35","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1046\/j.1365-2141.1998.01014.x","article-title":"Long-term administration of G-CSF for aplastic anemia is closely related to the early evolution of monosomy 7 MDS in adults.","volume":"103","author":"Kaito","year":"1998","journal-title":"Br J Hematol."},{"key":"2020021221165019300_B36","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1182\/blood.V96.6.2049","article-title":"Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia.","volume":"96","author":"Kojima","year":"2000","journal-title":"Blood."},{"key":"2020021221165019300_B37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0037-1963(00)90031-3","article-title":"Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy. The European Group for Blood and Marrow Transplantation experience.","volume":"37","author":"Bacigalupo","year":"2000","journal-title":"Semin Hematol."},{"key":"2020021221165019300_B38","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood.V84.3.923.923","article-title":"An increased HLA DR2 frequency is seen in aplastic anemia patients.","volume":"84","author":"Nimer","year":"1994","journal-title":"Blood."},{"key":"2020021221165019300_B39","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1182\/blood.V98.13.3513","article-title":"Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and PNH\/aplastic anemia syndrome.","volume":"98","author":"Maciejewski","year":"2001","journal-title":"Blood."},{"key":"2020021221165019300_B40"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/99\/9\/3129\/1682749\/h80902003129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/99\/9\/3129\/1682749\/h80902003129.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T02:17:39Z","timestamp":1581560259000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/99\/9\/3129\/53619\/Distinct-clinical-outcomes-for-cytogenetic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5,1]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2002,5,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v99.9.3129","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2002,5,1]]}}}